TY - JOUR
T1 - Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?
AU - De Carolis, Sara
AU - Botta, Angela
AU - Mekinian, Arsene
AU - Costedoat-Chalumeau, Nathalie
AU - Masseau, Agathe
AU - Tincani, Angela
AU - Alijotas-Reig, Jaume
AU - Ambrozic, Ales
AU - Le Guern, Véronique
AU - Fritsch-Stork, Ruth
AU - Nicaise-Roland, Pascale
AU - Carbonne, Bruno
AU - Carbillon, Lionel
AU - Fain, Olivier
PY - 2015
Y1 - 2015
N2 - The use of the conventional APS treatment (the combination of low-dose aspirin and LMWH) dramatically improved the obstetrical prognosis in primary obstetrical APS (OAPS). The persistence of adverse pregnancy outcome raises the need to find other drugs to improve obstetrical outcome. Hydroxychloroquine is widely used in patients with various autoimmune diseases, particularly SLE. Antimalarials have many anti-inflammatory, anti-aggregant and immune-regulatory properties: they inhibit phospholipase activity, stabilize lysosomal membranes, block the production of several pro-inflammatory cytokines and, in addition, impair complement-dependent antigen-antibody reactions. There is ample evidence of protective effects of hydroxychloroquine in OAPS similar to the situation in SLE arising from in vitro studies of pathophysiological working mechanism of hydroxychloroquine. However, the clinical data on the use of hydroxychloroquine in primary APS are lacking and prospective studies are necessary.
AB - The use of the conventional APS treatment (the combination of low-dose aspirin and LMWH) dramatically improved the obstetrical prognosis in primary obstetrical APS (OAPS). The persistence of adverse pregnancy outcome raises the need to find other drugs to improve obstetrical outcome. Hydroxychloroquine is widely used in patients with various autoimmune diseases, particularly SLE. Antimalarials have many anti-inflammatory, anti-aggregant and immune-regulatory properties: they inhibit phospholipase activity, stabilize lysosomal membranes, block the production of several pro-inflammatory cytokines and, in addition, impair complement-dependent antigen-antibody reactions. There is ample evidence of protective effects of hydroxychloroquine in OAPS similar to the situation in SLE arising from in vitro studies of pathophysiological working mechanism of hydroxychloroquine. However, the clinical data on the use of hydroxychloroquine in primary APS are lacking and prospective studies are necessary.
KW - Anti-Inflammatory Agents
KW - Antiphospholipid Syndrome
KW - Antiphospholipid syndrome
KW - Female
KW - Humans
KW - Hydroxychloroquine
KW - Outcome
KW - Pregnancy
KW - Pregnancy Complications
KW - Pregnancy Outcome
KW - Prognosis
KW - Anti-Inflammatory Agents
KW - Antiphospholipid Syndrome
KW - Antiphospholipid syndrome
KW - Female
KW - Humans
KW - Hydroxychloroquine
KW - Outcome
KW - Pregnancy
KW - Pregnancy Complications
KW - Pregnancy Outcome
KW - Prognosis
UR - http://hdl.handle.net/10807/72235
U2 - 10.1016/j.autrev.2014.08.040
DO - 10.1016/j.autrev.2014.08.040
M3 - Article
VL - 14
SP - 23
EP - 29
JO - AUTOIMMUNITY REVIEWS
JF - AUTOIMMUNITY REVIEWS
SN - 1873-0183
ER -